Eurofins CDMO Alphora announces completion of a new pilot scale biologics development facility

Sidra Satti, Marketing Specialist, Eurofins CDMO Alphora Inc., sidra.satti@bpt.eurofinsca.com

In an unwavering commitment to being collaborative partners in life-saving therapy development, Eurofins CDMO Alphora Inc. has seamlessly integrated existing experience in API and HPAPI with robust biologics capacity at the completion of its biologics pilot scale facility.

Facility highlights:

Spanning 3,300 square feet in Mississauga, Canada, capabilities at the pilot biologics facility include analytical services, upstream & downstream development, process design and gap analysis, process scale up, bioassays, and cGMP quality documentation. The facility uses mammalian cell culture for the production of therapeutic proteins and mAbs, as well as the use of other feedstocks, including transgenic plants, transgenic milks, and plasma. Leveraging advanced technology, Eurofins Alphora’s facility adeptly manages diverse batch sizes. With 200 L fed-batch and perfusion capabilities, the biologics laboratories can meet large-scale projects.

Expansion and growth:

Supported by a skilled team and state-of-the-art equipment, the facility optimises timelines in manufacturing biologic drug candidates. Furthermore, numerous new bioassays and protocols have been added across cell-based functional and binding assays. With advanced separation techniques for enhanced process performance, Eurofins Alphora is well suited to be your CDMO partner to fast track your product to market.

Integrated ADC Services:

By consolidating our deep expertise in linker and warhead development with our new biologics manufacturing capacity, we now offer an end-to-end solution for antibody drug conjugate (ADC) production, all under one roof. For more information, visit: www.eurofins.com/biopharma-services/cdmo/eurofins-alphora/ or Contact Us.